Global Neulasta (Pegfilgrastim) and Biosimilar Market Growth 2026-2032
The global Neulasta (Pegfilgrastim) and Biosimilar market size is predicted to grow from US$ 2834 million in 2025 to US$ 4438 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
United States market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Neulasta (Pegfilgrastim) and Biosimilar players cover Amgen, Viatris, Coherus, Novartis, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Neulasta (Pegfilgrastim) and Biosimilar Industry Forecast” looks at past sales and reviews total world Neulasta (Pegfilgrastim) and Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Neulasta (Pegfilgrastim) and Biosimilar sales for 2026 through 2032. With Neulasta (Pegfilgrastim) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neulasta (Pegfilgrastim) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Neulasta (Pegfilgrastim) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neulasta (Pegfilgrastim) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neulasta (Pegfilgrastim) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neulasta (Pegfilgrastim) and Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neulasta (Pegfilgrastim) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Neulasta (Pegfilgrastim) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
United States market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Neulasta (Pegfilgrastim) and Biosimilar players cover Amgen, Viatris, Coherus, Novartis, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Neulasta (Pegfilgrastim) and Biosimilar Industry Forecast” looks at past sales and reviews total world Neulasta (Pegfilgrastim) and Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Neulasta (Pegfilgrastim) and Biosimilar sales for 2026 through 2032. With Neulasta (Pegfilgrastim) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neulasta (Pegfilgrastim) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Neulasta (Pegfilgrastim) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neulasta (Pegfilgrastim) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neulasta (Pegfilgrastim) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neulasta (Pegfilgrastim) and Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neulasta (Pegfilgrastim) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Neulasta (Pegfilgrastim) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Brand
- Biosimilar
- Hospital
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Viatris
- Coherus
- Novartis
- Pfizer
- Amneal Pharmaceutical
- Fresenius Kabi
- What is the 10-year outlook for the global Neulasta (Pegfilgrastim) and Biosimilar market?
- What factors are driving Neulasta (Pegfilgrastim) and Biosimilar market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Neulasta (Pegfilgrastim) and Biosimilar market opportunities vary by end market size?
- How does Neulasta (Pegfilgrastim) and Biosimilar break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Neulasta (Pegfilgrastim) and Biosimilar by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Neulasta (Pegfilgrastim) and Biosimilar by Country/Region, 2021, 2025 & 2032
2.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
2.2.1 Brand
2.2.2 Biosimilar
2.2.3 Neulasta (Pegfilgrastim) and Biosimilar Sales by Type
2.2.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
2.2.3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Type (2021-2026)
2.3 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
2.3.1 Hospital
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Neulasta (Pegfilgrastim) and Biosimilar Sales by Application
2.3.4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Market Share by Application (2021-2026)
2.3.4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Breakdown Data by Company
3.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales by Company (2021-2026)
3.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Company (2021-2026)
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue by Company (2021-2026)
3.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Company (2021-2026)
3.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Company (2021-2026)
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Company
3.4 Key Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Product Location Distribution
3.4.2 Players Neulasta (Pegfilgrastim) and Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR BY GEOGRAPHIC REGION
4.1 World Historic Neulasta (Pegfilgrastim) and Biosimilar Market Size by Geographic Region (2021-2026)
4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country/Region (2021-2026)
4.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales by Country/Region (2021-2026)
4.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue by Country/Region (2021-2026)
4.3 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
4.4 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
4.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
4.6 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
5 AMERICAS
5.1 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
5.1.1 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026)
5.1.2 Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026)
5.2 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
5.3 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
6.1.1 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2021-2026)
6.1.2 APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2021-2026)
6.2 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
6.3 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neulasta (Pegfilgrastim) and Biosimilar by Country
7.1.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026)
7.1.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026)
7.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
7.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar by Country
8.1.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026)
8.1.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026)
8.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
8.3 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neulasta (Pegfilgrastim) and Biosimilar
10.3 Manufacturing Process Analysis of Neulasta (Pegfilgrastim) and Biosimilar
10.4 Industry Chain Structure of Neulasta (Pegfilgrastim) and Biosimilar
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors
11.3 Neulasta (Pegfilgrastim) and Biosimilar Customer
12 WORLD FORECAST REVIEW FOR NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR BY GEOGRAPHIC REGION
12.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region
12.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Forecast by Region (2027-2032)
12.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Neulasta (Pegfilgrastim) and Biosimilar Forecast by Type (2027-2032)
12.7 Global Neulasta (Pegfilgrastim) and Biosimilar Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Viatris
13.2.1 Viatris Company Information
13.2.2 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Viatris Main Business Overview
13.2.5 Viatris Latest Developments
13.3 Coherus
13.3.1 Coherus Company Information
13.3.2 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Coherus Main Business Overview
13.3.5 Coherus Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Amneal Pharmaceutical
13.6.1 Amneal Pharmaceutical Company Information
13.6.2 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Amneal Pharmaceutical Main Business Overview
13.6.5 Amneal Pharmaceutical Latest Developments
13.7 Fresenius Kabi
13.7.1 Fresenius Kabi Company Information
13.7.2 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Fresenius Kabi Main Business Overview
13.7.5 Fresenius Kabi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Neulasta (Pegfilgrastim) and Biosimilar by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Neulasta (Pegfilgrastim) and Biosimilar by Country/Region, 2021, 2025 & 2032
2.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
2.2.1 Brand
2.2.2 Biosimilar
2.2.3 Neulasta (Pegfilgrastim) and Biosimilar Sales by Type
2.2.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
2.2.3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Type (2021-2026)
2.3 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
2.3.1 Hospital
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Neulasta (Pegfilgrastim) and Biosimilar Sales by Application
2.3.4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Market Share by Application (2021-2026)
2.3.4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Breakdown Data by Company
3.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales by Company (2021-2026)
3.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Company (2021-2026)
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue by Company (2021-2026)
3.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Company (2021-2026)
3.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Company (2021-2026)
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Company
3.4 Key Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Product Location Distribution
3.4.2 Players Neulasta (Pegfilgrastim) and Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR BY GEOGRAPHIC REGION
4.1 World Historic Neulasta (Pegfilgrastim) and Biosimilar Market Size by Geographic Region (2021-2026)
4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country/Region (2021-2026)
4.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Sales by Country/Region (2021-2026)
4.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue by Country/Region (2021-2026)
4.3 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
4.4 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
4.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
4.6 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Growth
5 AMERICAS
5.1 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
5.1.1 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026)
5.1.2 Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026)
5.2 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
5.3 Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
6.1.1 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2021-2026)
6.1.2 APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2021-2026)
6.2 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
6.3 APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neulasta (Pegfilgrastim) and Biosimilar by Country
7.1.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026)
7.1.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026)
7.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
7.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar by Country
8.1.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026)
8.1.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026)
8.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026)
8.3 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neulasta (Pegfilgrastim) and Biosimilar
10.3 Manufacturing Process Analysis of Neulasta (Pegfilgrastim) and Biosimilar
10.4 Industry Chain Structure of Neulasta (Pegfilgrastim) and Biosimilar
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors
11.3 Neulasta (Pegfilgrastim) and Biosimilar Customer
12 WORLD FORECAST REVIEW FOR NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR BY GEOGRAPHIC REGION
12.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region
12.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Forecast by Region (2027-2032)
12.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Neulasta (Pegfilgrastim) and Biosimilar Forecast by Type (2027-2032)
12.7 Global Neulasta (Pegfilgrastim) and Biosimilar Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Viatris
13.2.1 Viatris Company Information
13.2.2 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Viatris Main Business Overview
13.2.5 Viatris Latest Developments
13.3 Coherus
13.3.1 Coherus Company Information
13.3.2 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Coherus Main Business Overview
13.3.5 Coherus Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Amneal Pharmaceutical
13.6.1 Amneal Pharmaceutical Company Information
13.6.2 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Amneal Pharmaceutical Main Business Overview
13.6.5 Amneal Pharmaceutical Latest Developments
13.7 Fresenius Kabi
13.7.1 Fresenius Kabi Company Information
13.7.2 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
13.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Fresenius Kabi Main Business Overview
13.7.5 Fresenius Kabi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neulasta (Pegfilgrastim) and Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Neulasta (Pegfilgrastim) and Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Brand
Table 4. Major Players of Biosimilar
Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Neulasta (Pegfilgrastim) and Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Neulasta (Pegfilgrastim) and Biosimilar Products Offered
Table 22. Neulasta (Pegfilgrastim) and Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Neulasta (Pegfilgrastim) and Biosimilar
Table 52. Key Market Challenges & Risks of Neulasta (Pegfilgrastim) and Biosimilar
Table 53. Key Industry Trends of Neulasta (Pegfilgrastim) and Biosimilar
Table 54. Neulasta (Pegfilgrastim) and Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Neulasta (Pegfilgrastim) and Biosimilar Distributors List
Table 57. Neulasta (Pegfilgrastim) and Biosimilar Customer List
Table 58. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Amgen Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 74. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Amgen Main Business
Table 76. Amgen Latest Developments
Table 77. Viatris Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 79. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Viatris Main Business
Table 81. Viatris Latest Developments
Table 82. Coherus Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 84. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Coherus Main Business
Table 86. Coherus Latest Developments
Table 87. Novartis Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 89. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Novartis Main Business
Table 91. Novartis Latest Developments
Table 92. Pfizer Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 93. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 94. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Pfizer Main Business
Table 96. Pfizer Latest Developments
Table 97. Amneal Pharmaceutical Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 98. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 99. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Amneal Pharmaceutical Main Business
Table 101. Amneal Pharmaceutical Latest Developments
Table 102. Fresenius Kabi Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 103. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 104. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Fresenius Kabi Main Business
Table 106. Fresenius Kabi Latest Developments
Table 1. Neulasta (Pegfilgrastim) and Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Neulasta (Pegfilgrastim) and Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Brand
Table 4. Major Players of Biosimilar
Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Neulasta (Pegfilgrastim) and Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Neulasta (Pegfilgrastim) and Biosimilar Products Offered
Table 22. Neulasta (Pegfilgrastim) and Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Neulasta (Pegfilgrastim) and Biosimilar
Table 52. Key Market Challenges & Risks of Neulasta (Pegfilgrastim) and Biosimilar
Table 53. Key Industry Trends of Neulasta (Pegfilgrastim) and Biosimilar
Table 54. Neulasta (Pegfilgrastim) and Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Neulasta (Pegfilgrastim) and Biosimilar Distributors List
Table 57. Neulasta (Pegfilgrastim) and Biosimilar Customer List
Table 58. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Neulasta (Pegfilgrastim) and Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Amgen Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 74. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Amgen Main Business
Table 76. Amgen Latest Developments
Table 77. Viatris Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 79. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Viatris Main Business
Table 81. Viatris Latest Developments
Table 82. Coherus Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 84. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Coherus Main Business
Table 86. Coherus Latest Developments
Table 87. Novartis Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 89. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Novartis Main Business
Table 91. Novartis Latest Developments
Table 92. Pfizer Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 93. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 94. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Pfizer Main Business
Table 96. Pfizer Latest Developments
Table 97. Amneal Pharmaceutical Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 98. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 99. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Amneal Pharmaceutical Main Business
Table 101. Amneal Pharmaceutical Latest Developments
Table 102. Fresenius Kabi Basic Information, Neulasta (Pegfilgrastim) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 103. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolios and Specifications
Table 104. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Fresenius Kabi Main Business
Table 106. Fresenius Kabi Latest Developments
LIST OF FIGURES
Figure 1. Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Neulasta (Pegfilgrastim) and Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Neulasta (Pegfilgrastim) and Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Brand
Figure 12. Product Picture of Biosimilar
Figure 13. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Consumed in Hospital
Figure 16. Global Neulasta (Pegfilgrastim) and Biosimilar Market: Hospital (2021-2026) & (K Units)
Figure 17. Neulasta (Pegfilgrastim) and Biosimilar Consumed in Pharmacy
Figure 18. Global Neulasta (Pegfilgrastim) and Biosimilar Market: Pharmacy (2021-2026) & (K Units)
Figure 19. Neulasta (Pegfilgrastim) and Biosimilar Consumed in Other
Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market: Other (2021-2026) & (K Units)
Figure 21. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Market Share by Application (2025)
Figure 22. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application in 2026
Figure 23. Neulasta (Pegfilgrastim) and Biosimilar Sales by Company in 2026 (K Units)
Figure 24. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Company in 2026
Figure 25. Neulasta (Pegfilgrastim) and Biosimilar Revenue by Company in 2026 ($ millions)
Figure 26. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Company in 2026
Figure 27. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 30. Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 32. APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 34. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 37. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2026
Figure 38. Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 39. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 40. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 41. United States Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2026
Figure 46. APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2021-2026)
Figure 47. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 48. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 49. China Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. India Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2026
Figure 57. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 58. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 59. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 60. Germany Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. France Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 68. Egypt Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Neulasta (Pegfilgrastim) and Biosimilar in 2026
Figure 74. Manufacturing Process Analysis of Neulasta (Pegfilgrastim) and Biosimilar
Figure 75. Industry Chain Structure of Neulasta (Pegfilgrastim) and Biosimilar
Figure 76. Channels of Distribution
Figure 77. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 78. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Neulasta (Pegfilgrastim) and Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Neulasta (Pegfilgrastim) and Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Brand
Figure 12. Product Picture of Biosimilar
Figure 13. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Consumed in Hospital
Figure 16. Global Neulasta (Pegfilgrastim) and Biosimilar Market: Hospital (2021-2026) & (K Units)
Figure 17. Neulasta (Pegfilgrastim) and Biosimilar Consumed in Pharmacy
Figure 18. Global Neulasta (Pegfilgrastim) and Biosimilar Market: Pharmacy (2021-2026) & (K Units)
Figure 19. Neulasta (Pegfilgrastim) and Biosimilar Consumed in Other
Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market: Other (2021-2026) & (K Units)
Figure 21. Global Neulasta (Pegfilgrastim) and Biosimilar Sale Market Share by Application (2025)
Figure 22. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application in 2026
Figure 23. Neulasta (Pegfilgrastim) and Biosimilar Sales by Company in 2026 (K Units)
Figure 24. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Company in 2026
Figure 25. Neulasta (Pegfilgrastim) and Biosimilar Revenue by Company in 2026 ($ millions)
Figure 26. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Company in 2026
Figure 27. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 30. Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 32. APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 34. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 37. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2026
Figure 38. Americas Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 39. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 40. Americas Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 41. United States Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2026
Figure 46. APAC Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2021-2026)
Figure 47. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 48. APAC Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 49. China Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. India Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2026
Figure 57. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 58. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 59. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 60. Germany Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. France Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 68. Egypt Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Neulasta (Pegfilgrastim) and Biosimilar in 2026
Figure 74. Manufacturing Process Analysis of Neulasta (Pegfilgrastim) and Biosimilar
Figure 75. Industry Chain Structure of Neulasta (Pegfilgrastim) and Biosimilar
Figure 76. Channels of Distribution
Figure 77. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 78. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share Forecast by Application (2027-2032)
